NASDAQ:SRPT - Sarepta Therapeutics Stock Price, News, & Analysis

$156.91
+0.81 (+0.52 %)
(As of 07/16/2019 08:00 AM ET)
Today's Range
$155.26
Now: $156.91
$158.80
50-Day Range
$113.85
MA: $133.73
$158.10
52-Week Range
$95.21
Now: $156.91
$165.87
Volume1.06 million shs
Average Volume1.64 million shs
Market Capitalization$11.63 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.12
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SRPT
Previous SymbolNASDAQ:AVII
CUSIPN/A
Phone617-274-4000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$301.03 million
Book Value$15.45 per share

Profitability

Net Income$-361,920,000.00
Net Margins-124.66%

Miscellaneous

Employees499
Market Cap$11.63 billion
Next Earnings Date8/14/2019 (Estimated)
OptionableOptionable

Receive SRPT News and Ratings via Email

Sign-up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter.

Sarepta Therapeutics (NASDAQ:SRPT) Frequently Asked Questions

What is Sarepta Therapeutics' stock symbol?

Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT."

How were Sarepta Therapeutics' earnings last quarter?

Sarepta Therapeutics Inc (NASDAQ:SRPT) posted its earnings results on Wednesday, May, 8th. The biotechnology company reported ($1.07) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($2.05) by $0.98. The biotechnology company had revenue of $87.01 million for the quarter, compared to analyst estimates of $86.92 million. Sarepta Therapeutics had a negative net margin of 124.66% and a negative return on equity of 36.26%. View Sarepta Therapeutics' Earnings History.

When is Sarepta Therapeutics' next earnings date?

Sarepta Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August 14th 2019. View Earnings Estimates for Sarepta Therapeutics.

What price target have analysts set for SRPT?

18 analysts have issued 1-year price objectives for Sarepta Therapeutics' stock. Their forecasts range from $170.00 to $270.00. On average, they expect Sarepta Therapeutics' share price to reach $211.6250 in the next twelve months. This suggests a possible upside of 34.9% from the stock's current price. View Analyst Price Targets for Sarepta Therapeutics.

What is the consensus analysts' recommendation for Sarepta Therapeutics?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last year. There are currently 18 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sarepta Therapeutics.

What are Wall Street analysts saying about Sarepta Therapeutics stock?

Here are some recent quotes from research analysts about Sarepta Therapeutics stock:
  • 1. According to Zacks Investment Research, "Sarepta's Exondys 51 has witnessed impressive growth in 2018. Sarepta is also focused on reimbursement programs for better accessibility of the drug. Moreover, a potential approval to golodirsen will boost the company’s prospect as it will increase eligible patient population. Sarepta’s continues to progress with its DMD pipeline. The company is collaborating with companies and academic institutions to boost its DMD pipeline. However, dependence on a single product, Exondys 51, remains a concern. Meanwhile in December 2018, the company received a setback as it failed to gain approval for Exondys 51 in the EU. The DMD market is getting competitive as several other companies are developing therapies. The company’s shares have underperformed the industry so far this year. Loss estimates have narrowed ahead of the company’s Q1 earnings release. The company has a mixed record of earnings surprises in the recent quarters." (5/8/2019)
  • 2. Cantor Fitzgerald analysts commented, ": Reiterate our Overweight rating and 12-mo. PT of $217. From our conversations with investors, we believe that awareness on limb girdle is increasing, but it remains low. We are publishing our 35-page prep pack discussing the disease, data expectations and potential stock moves. Sarepta will disclose 60- day biopsy data for MYO-101 in LGMD2E patients on Wed. morning (2/27). This is the first of five limb girdle readouts in the pipeline, which we think could drive significant upside to current valuation and diversify Sarepta beyond DMD. Sarepta remains a top pick." (2/22/2019)
  • 3. HC Wainwright analysts commented, "Our $267 price target is derived from a risk-adjusted (does not include CMT or Sanfilippo A) DCF analysis and is based on: beta of 1.42, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 7.4%, and tax rate of 15% beginning in FY 2024." (1/4/2019)

Has Sarepta Therapeutics been receiving favorable news coverage?

Media stories about SRPT stock have trended very negative on Tuesday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Sarepta Therapeutics earned a coverage optimism score of -3.2 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 3.0 out of 10, meaning that recent media coverage is unlikely to have an effect on the company's share price in the next few days. View News Stories for Sarepta Therapeutics.

Who are some of Sarepta Therapeutics' key competitors?

What other stocks do shareholders of Sarepta Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), Micron Technology (MU), NVIDIA (NVDA), Netflix (nflx), Gilead Sciences (GILD), Alibaba Group (BABA), Bausch Health Companies (BHC), Advanced Micro Devices (AMD), ACADIA Pharmaceuticals (ACAD) and Sophiris Bio (SPHS).

Who are Sarepta Therapeutics' key executives?

Sarepta Therapeutics' management team includes the folowing people:
  • Mr. Douglas S. Ingram, Pres, CEO & Director (Age 56)
  • Mr. Sandesh Mahatme LL.M., Exec. VP, CFO & Chief Bus. Officer (Age 54)
  • Mr. David Tyronne Howton Jr., Exec. VP, Gen. Counsel & Corp. Sec. (Age 47)
  • Mr. Alexander Bo Cumbo, Exec. VP & Chief Commercial Officer (Age 48)
  • Dr. Edward M. Kaye, Advisor (Age 70)

Who are Sarepta Therapeutics' major shareholders?

Sarepta Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Handelsbanken Fonder AB (0.03%), EFG Asset Management Americas Corp. (0.03%), Harbour Capital Advisors LLC (0.01%), Fagan Associates Inc. (0.01%), WINTON GROUP Ltd (0.01%) and E&G Advisors LP (0.00%). Company insiders that own Sarepta Therapeutics stock include Alexander Cumbo, David T Howton, Douglas S Ingram, Edward M Md Kaye, Hans Lennart Rudolf Wigzell, Richard Barry, Sandesh Mahatme and Shamim Ruff. View Institutional Ownership Trends for Sarepta Therapeutics.

Which institutional investors are selling Sarepta Therapeutics stock?

SRPT stock was sold by a variety of institutional investors in the last quarter, including Handelsbanken Fonder AB and WINTON GROUP Ltd. Company insiders that have sold Sarepta Therapeutics company stock in the last year include David T Howton, Hans Lennart Rudolf Wigzell and Sandesh Mahatme. View Insider Buying and Selling for Sarepta Therapeutics.

Which institutional investors are buying Sarepta Therapeutics stock?

SRPT stock was acquired by a variety of institutional investors in the last quarter, including Fagan Associates Inc., EFG Asset Management Americas Corp., Harbour Capital Advisors LLC, E&G Advisors LP, Evolution Wealth Advisors LLC and Nisa Investment Advisors LLC. View Insider Buying and Selling for Sarepta Therapeutics.

How do I buy shares of Sarepta Therapeutics?

Shares of SRPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sarepta Therapeutics' stock price today?

One share of SRPT stock can currently be purchased for approximately $156.91.

How big of a company is Sarepta Therapeutics?

Sarepta Therapeutics has a market capitalization of $11.63 billion and generates $301.03 million in revenue each year. The biotechnology company earns $-361,920,000.00 in net income (profit) each year or ($5.46) on an earnings per share basis. Sarepta Therapeutics employs 499 workers across the globe.View Additional Information About Sarepta Therapeutics.

What is Sarepta Therapeutics' official website?

The official website for Sarepta Therapeutics is http://www.sareptatherapeutics.com/.

How can I contact Sarepta Therapeutics?

Sarepta Therapeutics' mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-274-4000 or via email at [email protected]


MarketBeat Community Rating for Sarepta Therapeutics (NASDAQ SRPT)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  1,203 (Thanks for Voting!)
Underperform Votes:  707 (Thanks for Voting!)
Total Votes:  1,910
MarketBeat's community ratings are surveys of what our community members think about Sarepta Therapeutics and other stocks. Vote "Outperform" if you believe SRPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel